{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009791","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.288715+00:00","generated_at":"2026-05-16T10:50:53.676301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx prelim 2025 revenue $672-674M beats guidance; cash $735M; two gene therapy approvals possible in 2026","bullets":["Preliminary FY2025 total revenue $672-674M, ~20% YoY, exceeding top end of guidance.","Crysvita revenue $480-482M (17% YoY, above guidance); Dojolvi $95-97M (9% YoY, at guidance midpoint).","Cash and investments ~$735M at year-end 2025; full Q4/FY results and 2026 guidance due Feb 2026.","2026 catalysts: DTX401 (GSDIa) PDUFA Q3; UX111 (MPS IIIA) BLA resubmission early 2026; GTX-102 (Angelman) Phase 3 data H2 2026.","UX701 (Wilson disease) pivotal data H1 2026; UX143 (osteogenesis imperfecta) data presented at JPM conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009791","json":"https://secwatch.observer/filing/0001193125-26-009791.json","markdown":"https://secwatch.observer/filing/0001193125-26-009791.md","text":"https://secwatch.observer/filing/0001193125-26-009791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/0001193125-26-009791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:53.676301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}